What's Next After Trump Nearly Ended Trade Talks With Canada
After markets closed last Friday, U.S. President Trump said he was ending all trade talks with Canada. He pointed to the digital services tax on U.S. technology companies as the reason. On Monday, Prime Minister Carney abruptly rescinded the DST. While trade talks may resume, economic risks remain.The automotive sector will suffer the most in Canada, the U.S., and Mexico. Canada and Mexico are both the main importers of U.S. vehicles and vehicle parts. Firms have an integrated supply chain, resulting from 30 years of free trade. Investors should be wary of General Motors (GM), Ford (F), and especially Stellantis (STLA). Despite withdrawing its guidance for the full year, F stock is in an uptrend. Investors are likely betting that the U.S. will concede to sustain trading volumes among the countries.DST Rescinded Trump had characterized Canada as a difficult country to trade with, referencing the Digital Services Tax. However, now that Carney cancelled the DST, services firm will not need to pay a 3% tax on revenue from online users. This reversal should help Netflix (NFLX), Alphabet (GOOG), and Meta Platforms (META). Investors should watch the Canadian Index (EWC), its currency (FXC), and the U.S. dollar (DXY). The U.S. dollar continued to weaken from January through April. It rallied briefly in May, only to continue toward multi-year lows.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


